| First Author | Liu Q | Year | 2024 |
| Journal | Cancer Lett | Volume | 583 |
| Pages | 216585 | PubMed ID | 38101607 |
| Mgi Jnum | J:344561 | Mgi Id | MGI:7578605 |
| Doi | 10.1016/j.canlet.2023.216585 | Citation | Liu Q, et al. (2023) CMTM6 promotes hepatocellular carcinoma progression through stabilizing beta-catenin. Cancer Lett 583:216585 |
| abstractText | CMTM6, a regulator of PD-L1 stability, has been implicated in the development of various cancers. However, the expression and role of CMTM6 in hepatocellular carcinoma (HCC) remains controversial. Our study revealed a negative correlation between CMTM6 expression and HCC prognosis through bioinformatics analysis and immunofluorescence staining. CMTM6 expression was also positively associated with alpha-fetoprotein (AFP) levels, supporting its potential as a prognostic marker for HCC. Using Cmtm6 knockout mice, we found that Cmtm6 deficiency inhibited HCC formation and cell proliferation in primary liver cancer models induced by DEN and DEN/CCl(4). In HCC cell lines, CMTM6 promoted cell proliferation and interacted with beta-catenin, stabilizing it by preventing ubiquitination. In conclusion, our study suggested that CMTM6 upregulation promotes HCC cell proliferation through the beta-catenin pathway, making it a potential therapeutic target for HCC treatment. |
